These findings position NUAK2 as a key mediator of the ECM–Hippo–YAP/TAZ axis in GBM, offering potential avenues for therapeutic intervention through ECM modulation and targeted pathway inhibition. This evidence concerns the gene NUAK2 and glioblastoma.